동아에스티

170900KOSPI의약품 제조업

45.8 / 100

Reference Date: 2026-04-13

Financial Score12.0 / 40

News Sentiment14.8 / 25

Momentum9.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but the high debt ratio poses financial risk. Slightly up 3.0% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Dong-A ST, established in 2013 through a spin-off from Dong-A Pharmaceutical, focuses on manufacturing and selling specialty pharmaceuticals, medical devices, and pharmaceutical cosmetics. Key products include Grotrixin, Motiriton, and Suganon, with 2024 sales reaching 697.9 billion won, a 5.1% increase from the previous year. Growth was driven by the biopharmaceutical product Grotrixin and increased overseas exports.

Number of Employees

1,685people

Average Salary

78.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 14.804.0Point

PBR

0.63Industry Average 1.045.5Point

Lower than industry avg (good)

ROE

-5.45Industry Average 4.420.0Point

Well below industry avg

Debt Ratio

49.87Industry Average 11.980.0Point

4.2x industry avg (risky)

Trend 2023~20252.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲10.5% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼110.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -2.8% (declining, 3yr)

Detailed News Sentiment

16 totalPositive 6Neutral 5Negative 0Average Sentiment Score 63.6

Detailed Momentum

52-week position3.0Point

52w lower range (30%)

Current 45,350Won52-week high 55,12552-week low 41,010

1-month return4.0Point

1m +2.95% (slight rise)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

24 totalPositive 0Neutral 24Negative 0

Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-04-03
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-31
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-31
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-31
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-31